Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.88% |
| Dec 31, 2025 | -15.07% |
| Sep 30, 2025 | 41.32% |
| Jun 30, 2025 | 6.19% |
| Mar 31, 2025 | -26.73% |
| Dec 31, 2024 | 24.84% |
| Sep 30, 2024 | 19.26% |
| Jun 30, 2024 | 4.85% |
| Mar 31, 2024 | 19.38% |
| Dec 31, 2023 | 51.08% |
| Sep 30, 2023 | 10.36% |
| Jun 30, 2023 | 78.56% |
| Mar 31, 2023 | -12.87% |
| Dec 31, 2022 | 66.80% |
| Sep 30, 2022 | 52.16% |
| Jun 30, 2022 | 22.61% |
| Mar 31, 2022 | 16.82% |
| Dec 31, 2021 | -16.33% |
| Sep 30, 2021 | 21.02% |
| Jun 30, 2021 | 24.80% |